Show simple item record

dc.contributor.authorNaseem, Sumbal
dc.contributor.authorHassan, Muhammad
dc.contributor.authorAkhtar, Shazia Nasim
dc.contributor.authorSyed, Fibhaa
dc.contributor.authorKhan, Naveed Ullah
dc.contributor.authorUsman, Muhammad
dc.date.accessioned2022-04-20T01:01:54Z
dc.date.available2022-04-20T01:01:54Z
dc.date.issued2022-03-04
dc.identifierpubmed: 35382194
dc.identifierdoi: 10.7759/cureus.22843
dc.identifierpmc: PMC8977061
dc.identifier.citationCureus, volume 14, issue 3, page e22843
dc.identifier.urihttp://hdl.handle.net/10034/626811
dc.descriptionFrom PubMed via Jisc Publications Router
dc.descriptionHistory: accepted 2022-03-03
dc.descriptionPublication status: epublish
dc.description.abstractBackground Chronic obstructive pulmonary disease (COPD) is a chronic airflow obstructive condition. The mainstay of treatment is to avoid exacerbation and manage the symptoms. Roflumilast is being used as a part of treatment to reduce the inflammatory process in this disease. Method This systematic review and meta-analysis were conducted following the provided guidelines. PubMed, Cochrane Library, and Cinahl were considered for searching the desired studies selected until 19 June 2021. The eligibility criteria for inclusion and exclusion were set before selecting studies. Result Five hundred eighty (580) studies were identified at the beginning. Removal of duplicates was done using Endnote software. The eligibility criteria, including the randomized controlled trial study design and others, were applied for screening the title and abstracts. Six studies were selected for the qualitative analysis. After assessing the data from these studies, it was found that roflumilast is an effective drug to treat COPD. Roflumilast plays an essential role in improving quality of life, inflammatory process, and clinical improvement. The drug's mild to moderate adverse effects were observed, but no significant severe adverse events were reported, and the drug was well tolerated. Conclusion Roflumilast is a valuable drug that can be used for its beneficial effects on COPD exacerbation. The benefits of the drug outweigh its adverse effects. [Abstract copyright: Copyright © 2022, Naseem et al.]
dc.languageeng
dc.sourcepissn: 2168-8184
dc.subjectroflumilast
dc.subjectchronic obstructive pulmonary disease
dc.subjectsafety
dc.subjectsystematic review and meta analysis
dc.subjectefficacy
dc.titleEffectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
dc.typearticle
dc.date.updated2022-04-20T01:01:54Z
dc.date.accepted2022-03-03


This item appears in the following Collection(s)

Show simple item record